InSilico Medicine Hong Kong Limited

🇭🇰Hong Kong, China
Ownership
-
Employees
-
Market Cap
-
Website
Clinical Trials
Related News

Study of ISM5939 in Patients With Advanced and/or Metastatic Solid Tumors

First Posted Date
2024-12-09
Last Posted Date
2024-12-09
Lead Sponsor
InSilico Medicine Hong Kong Limited
Target Recruit Count
159
Registration Number
NCT06724042

Study of ISM6331 in Participants With Advanced/Metastatic Malignant Mesothelioma or Other Solid Tumors

First Posted Date
2024-08-22
Last Posted Date
2024-12-06
Lead Sponsor
InSilico Medicine Hong Kong Limited
Target Recruit Count
82
Registration Number
NCT06566079

Study Evaluating ISM8207 in Participants With Advanced Solid Tumors and Relapsed/Refractory B-Cell Lymphoma

First Posted Date
2024-06-06
Last Posted Date
2024-06-07
Lead Sponsor
InSilico Medicine Hong Kong Limited
Target Recruit Count
60
Registration Number
NCT06445517
Locations
🇨🇳

Beijing Cancer Hospital, Beijing, Beijing, China

🇨🇳

Shanghai Jiao Tong University School of Medicine-Ruijin Hospital, Shanghai, Shanghai, China

Study of ISM3412 in Participants With Locally Advanced/Metastatic Solid Tumors

Phase 1
Not yet recruiting
Conditions
Locally Advanced/Metastatic Solid Tumors
Interventions
Drug: ISM3412
First Posted Date
2024-05-16
Last Posted Date
2024-05-16
Lead Sponsor
InSilico Medicine Hong Kong Limited
Target Recruit Count
80
Registration Number
NCT06414460

Study Evaluating ISM5411 Administered Orally to Healthy Volunteers

Phase 1
Completed
Conditions
Healthy Subjects
Interventions
Drug: ISM5411
Drug: Placebo
First Posted Date
2023-08-25
Last Posted Date
2024-11-07
Lead Sponsor
InSilico Medicine Hong Kong Limited
Target Recruit Count
79
Registration Number
NCT06012578
Locations
🇦🇺

Nucleus Network, Melbourne, Victoria, Australia

Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis

First Posted Date
2023-08-04
Last Posted Date
2024-07-29
Lead Sponsor
InSilico Medicine Hong Kong Limited
Target Recruit Count
60
Registration Number
NCT05975983
Locations
🇺🇸

Bogan Sleep Consultants, LLC, Columbia, South Carolina, United States

🇺🇸

Keck School of Medicine of USC, Los Angeles, California, United States

🇺🇸

University of Oklahoma Health Sciences Center (OUHSC), Oklahoma City, Oklahoma, United States

and more 6 locations

Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis (IPF)

Phase 2
Active, not recruiting
Conditions
Idiopathic Pulmonary Fibrosis (IPF)
Interventions
Drug: Placebo
Drug: INS018_055
First Posted Date
2023-07-11
Last Posted Date
2024-06-18
Lead Sponsor
InSilico Medicine Hong Kong Limited
Target Recruit Count
70
Registration Number
NCT05938920
Locations
🇨🇳

Anhui Chest Hospital, Hefei, Anhui, China

🇨🇳

The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China

🇨🇳

Peking University Shougang Hospital, Beijing, Beijing, China

and more 19 locations

A Phase 1, Evaluate the Safety, Tolerability, and Pharmacokinetics of INS018_055 in Healthy Subjects

Phase 1
Completed
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Drug: Placebo
Drug: INS018_055
First Posted Date
2021-12-13
Last Posted Date
2023-06-29
Lead Sponsor
InSilico Medicine Hong Kong Limited
Target Recruit Count
78
Registration Number
NCT05154240
Locations
🇳🇿

NZCR Ltd, Christchurch, New Zealand

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy